BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a report issued on Friday morning.
REGN has been the topic of several other research reports. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $396.00 to $409.00 and gave the company an equal weight rating in a report on Friday, August 3rd. Argus increased their target price on shares of Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a buy rating in a report on Monday, July 16th. UBS Group raised shares of Regeneron Pharmaceuticals from a market perform rating to an outperform rating in a report on Wednesday, June 27th. Canaccord Genuity increased their target price on shares of Regeneron Pharmaceuticals from $390.00 to $410.00 and gave the company a hold rating in a report on Thursday, October 11th. Finally, Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, October 1st. They set a neutral rating and a $415.00 target price on the stock. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $410.95.
Shares of NASDAQ:REGN opened at $387.80 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62. Regeneron Pharmaceuticals has a one year low of $281.89 and a one year high of $437.90. The firm has a market capitalization of $42.12 billion, a PE ratio of 28.92, a P/E/G ratio of 1.30 and a beta of 1.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the firm earned $4.17 EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals will post 19.4 EPS for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $380.00, for a total value of $760,000.00. Following the completion of the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $5,320,000. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The disclosure for this sale can be found here. In the last three months, insiders sold 112,052 shares of company stock worth $45,411,762. Insiders own 12.42% of the company’s stock.
Several large investors have recently bought and sold shares of REGN. Icon Wealth Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $112,000. Signaturefd LLC lifted its position in shares of Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 198 shares during the period. Flagship Harbor Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $159,000. Summit Trail Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 22,971.8% in the 1st quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 165,627 shares during the period. Finally, Valeo Financial Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 943.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 500 shares during the period. 66.09% of the stock is owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Ex-Dividend
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.